<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665054</url>
  </required_header>
  <id_info>
    <org_study_id>11382</org_study_id>
    <nct_id>NCT00665054</nct_id>
  </id_info>
  <brief_title>BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction</brief_title>
  <official_title>Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is:- To assess the efficacy and tolerability of vardenafil in male
      subjects suffering from erectile dysfunction as compared to placebo- To assess the influence
      of vardenafil on the self-esteem and self-confidence of subjects suffering from erectile
      dysfunction following treatment with vardenafil as compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LOCF improved compared to baseline GAQ results at the end of the study</measure>
    <time_frame>baseline versus visit 2 visit 5 or premature termination visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IIEF scores</measure>
    <time_frame>visits 3, 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OF, SD, IS scores in IIEF Questionnaire</measure>
    <time_frame>visits 2, 3, 4, 5 or at premature termination visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of all individual questions on IIEF questionnaire</measure>
    <time_frame>visits 2, 3, 4, 5 or at premature termination visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's diary response</measure>
    <time_frame>baseline and after randomization per visit period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSES-E scores</measure>
    <time_frame>visits 2 and 5 or premature termination visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary score from the responses to SSES-E</measure>
    <time_frame>visits 2 and 5 or premature termination visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response scores and summary score from the responses to the SF-36</measure>
    <time_frame>visits 2 and 5 or premature termination visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levitra (Vardenafil, BAY38-9456)</intervention_name>
    <description>5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets orally prior to sexual activity</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with heterosexual relationships aged 18 - 64 years suffering from ED for more than
             6 months according to the NIH Consensus Statement (i.e. inability to attain and/or
             maintain penile erection sufficient for satisfactory sexual performance).

          -  At least 4 attempts at sexual intercourse (according to the question in the subject
             diary) on 4 separate days during the 4-week untreated baseline period. At least 50% of
             attempts during this period had to be unsuccessful according to the subject diary.

        Exclusion Criteria:

          -  Presence of penile anatomical abnormalities (eg penile fibrosis or Peyronie's disease)
             that in the investigator's opinion would significantly impair sexual performance.

          -  Primary hypoactive sexual desire.-Spinal cord injury-History of surgical prostatectomy
             (transurethral interventions not excluded).

          -  Unstable angina pectoris.

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within the
             prior 6 months.

          -  Uncontrolled atrial fibrillation/flutter at screening visit (ventricular response rate
             &gt;100 BPM).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antalya</city>
        <zip>07003</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vardenafil</keyword>
  <keyword>Erectile dysfunction</keyword>
  <keyword>SSES-E (sexual self-efficacy scale - erectile function)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

